Analysis on Impact of COVID-19- Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024 | Evolving Opportunities with Baxter International Inc. and Cipla Inc. | Technavio

·4 min read

The global chemotherapy-induced nausea and vomiting drugs market is expected to grow by USD 525 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of about 5%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200810005369/en/

Technavio has announced its latest market research report titled Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024 (Graphic: Business Wire)

Request challenges and opportunities that influence COVID-19 pandemic - Request Free Sample Report on COVID-19 Impacts

Read the 120-page report with TOC on "Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis Report by Therapy (Serotonin receptor antagonists, NK1 receptor antoagonists, and Others), Geography (North America, Europe, APAC, and ROW), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/chemotherapy-induced-nausea-and-vomiting-drugs-market-industry-analysis

The market is driven by increasing inorganic growth strategies. In addition, robust R&D activities are anticipated to boost the growth of chemotherapy-induced nausea and vomiting drugs market.

Vendors in the market are focusing on expanding their product portfolios and market presence by forming alliances with other players in the market. Such strategies also help them reduce R&D costs and penetrate the market quickly. For instance, in January 2019, GlaxoSmithKline completed the acquisition of TESARO Corp. The acquisition helped GlaxoSmithKline strengthen and reinforce its oncology pipeline. Many such mergers and acquisitions are expected to drive the growth of the global chemotherapy-induced nausea and vomiting drugs market during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Chemotherapy-induced Nausea and Vomiting Drugs Companies:

Baxter International Inc.

Baxter International Inc. operates its business through segments such as Americas, EMEA, and APAC. The company offers Ondansetron Hydrochloride. It is a serotonin receptor antagonist used for the treatment of chemotherapy-induced nausea and vomiting.

Cipla Inc.

Cipla Inc. operates its business through segments such as Pharmaceuticals and New ventures. The company offers EMESET. It is a serotonin receptor antagonist used for the treatment of chemotherapy-induced nausea and vomiting.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. operates its business through segments such as Pharmaceuticals and Diagnostics. The company offers Kytril. It contains granisetrona serotonin 5-HT2 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy.

GlaxoSmithKline Plc

GlaxoSmithKline Plc operates its business through segments such as Pharmaceuticals, Consumer healthcare, and Vaccines. The company offers Zofran. It contains ondansetron hydrochloride as the active ingredient and is available in the oral formulation and IV injection forms for the treatment of chemotherapy-induced nausea and vomiting.

Merck & Co. Inc.

Merck & Co. Inc. operates its business through segments such as Pharmaceuticals, Animal health, and Others. The company offers prodrug fosaprepitant dimeglumine, which is used for preventing CINV and post-operative nausea and vomiting.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Chemotherapy-induced Nausea and Vomiting Drugs Market Therapy Outlook (Revenue, USD Million, 2020-2024)

  • Serotonin receptor antagonists

  • NK1 receptor antoagonists

  • Others

Chemotherapy-induced Nausea and Vomiting Drugs Market Geography Outlook (Revenue, USD Million, 2020-2024)

  • North America

  • Europe

  • APAC

  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Actinic Keratosis Drugs Market – Global actinic keratosis drugs market drug class (nucleoside metabolic inhibitors, immunomodulators, photosensitizers, and NSAIDs) and geography (North America, APAC, Europe, and ROW).

Global Allergy Rhinitis Drugs Market – Global allergy rhinitis drugs market by product (antihistamines, intranasal corticosteroids, immunotherapies, and others) and geography (APAC, Europe, MEA, North America, and South America).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005369/en/

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/